Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 4
2017 7
2018 8
2019 19
2020 17
2021 26
2022 32
2023 23
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 34933889

101 results

Results by year

Filters applied: . Clear all
Page 1
Therapeutic efficacy, prognostic variables and clinical outcome of 177Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-à-vis Gleason score in such cohort.
Suman S, Parghane RV, Joshi A, Prabhash K, Bakshi G, Talole S, Banerjee S, Basu S. Suman S, et al. Br J Radiol. 2019 Dec;92(1104):20190380. doi: 10.1259/bjr.20190380. Epub 2019 Nov 1. Br J Radiol. 2019. PMID: 31600089 Free PMC article.
ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
Emmett L, Subramaniam S, Joshua AM, Crumbaker M, Martin A, Zhang AY, Rana N, Langford A, Mitchell J, Yip S, Francis R, Hofman MS, Sandhu S, Azad A, Gedye C, McJannett M, Stockler MR, Davis ID; Australian, New Zealand Urogenital, Prostate Cancer Trials Group (ANZUP), the ENZA-p investigators. Emmett L, et al. BJU Int. 2021 Nov;128(5):642-651. doi: 10.1111/bju.15491. Epub 2021 Jul 6. BJU Int. 2021. PMID: 34028967
The Impact of PSMA PET-Based Eligibility Criteria Used in the Prospective Phase II TheraP Trial in Metastatic Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Targeted Radioligand Therapy.
Karimzadeh A, Heck M, Tauber R, Solaris E, Nekolla S, Knorr K, Haller B, D'Alessandria C, Weber WA, Eiber M, Rauscher I. Karimzadeh A, et al. J Nucl Med. 2023 Aug;64(8):1252-1258. doi: 10.2967/jnumed.122.265346. Epub 2023 Jun 8. J Nucl Med. 2023. PMID: 37290796 Clinical Trial.
The Prognostic Value of Posttreatment 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN).
Pathmanandavel S, Crumbaker M, Nguyen A, Yam AO, Wilson P, Niman R, Ayers M, Sharma S, Eu P, Martin AJ, Stockler MR, Joshua AM, Emmett L. Pathmanandavel S, et al. J Nucl Med. 2023 Jan;64(1):69-74. doi: 10.2967/jnumed.122.264104. Epub 2022 Jun 23. J Nucl Med. 2023. PMID: 35738906 Free PMC article. Clinical Trial.
Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand therapy.
Rosar F, Wenner F, Khreish F, Dewes S, Wagenpfeil G, Hoffmann MA, Schreckenberger M, Bartholomä M, Ezziddin S. Rosar F, et al. Eur J Nucl Med Mol Imaging. 2022 Apr;49(5):1584-1594. doi: 10.1007/s00259-021-05594-8. Epub 2021 Nov 2. Eur J Nucl Med Mol Imaging. 2022. PMID: 34725725 Free PMC article.
Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy.
Thang SP, Violet J, Sandhu S, Iravani A, Akhurst T, Kong G, Ravi Kumar A, Murphy DG, Williams SG, Hicks RJ, Hofman MS. Thang SP, et al. Eur Urol Oncol. 2019 Nov;2(6):670-676. doi: 10.1016/j.euo.2018.11.007. Epub 2018 Dec 13. Eur Urol Oncol. 2019. PMID: 31412006 Clinical Trial.
101 results